Literature DB >> 1714663

Identification of residues in VP2 that contribute to poliovirus neutralization antigenic site 3B.

C Reynolds1, G Page, H Zhou, M Chow.   

Abstract

Amino acid substitutions were placed at residues 74, 243, and 246 in capsid protein VP2 of poliovirus serotype 1, using site-specific mutagenesis methods. The proximity of these residues to those previously identified in neutralization site 3B suggests that these residues may also contribute to neutralization site 3B and potentially be under antibody selective pressure to mutate. However, sequence analyses of independent serotype 1 isolates indicate high sequence conservation at these residues, suggesting selective pressures are present within the virus to maintain sequences within these loop regions. All viable mutants display partial or complete resistance to neutralization by the site 3B neutralizing monoclonal antibodies. Cross-neutralization data with the site-specifically generated viral mutants confirm that these residues do indeed contribute to forming neutralization site 3B and also identify the participation of a new loop region within site 3B. However, many amino acid substitutions generate nonviable virus mutants and even conservative amino acid substitutions produce growth-compromised virus mutants. These data suggest that previous definition of neutralization antigenic sites by isolation of neutralization resistant mutants favors detection of viable mutant viruses with more normal growth characteristics and is inherently biased against detection of neutralization antigenic sites formed by residues critical for other stages of virus replication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714663     DOI: 10.1016/0042-6822(91)90856-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.

Authors:  J T Stapleton; V Raina; P L Winokur; K Walters; D Klinzman; E Rosen; J H McLinden
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

2.  Efficient analysis of nonviable poliovirus capsid mutants.

Authors:  J Simons; A Rogove; N Moscufo; C Reynolds; M Chow
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

3.  Is the 135S poliovirus particle an intermediate during cell entry?

Authors:  Y Huang; J M Hogle; M Chow
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Three-dimensional structure of Theiler virus.

Authors:  R A Grant; D J Filman; R S Fujinami; J P Icenogle; J M Hogle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

5.  Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.

Authors:  Q Li; A G Yafal; Y M Lee; J Hogle; M Chow
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

6.  Folding and processing of the capsid protein precursor P1 is kinetically retarded in neutralization site 3B mutants of poliovirus.

Authors:  C Reynolds; D Birnby; M Chow
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  The structure of a neutralized virus: canine parvovirus complexed with neutralizing antibody fragment.

Authors:  W R Wikoff; G Wang; C R Parrish; R H Cheng; M L Strassheim; T S Baker; M G Rossmann
Journal:  Structure       Date:  1994-07-15       Impact factor: 5.006

8.  Structure of the major antigenic loop of foot-and-mouth disease virus complexed with a neutralizing antibody: direct involvement of the Arg-Gly-Asp motif in the interaction.

Authors:  N Verdaguer; M G Mateu; D Andreu; E Giralt; E Domingo; I Fita
Journal:  EMBO J       Date:  1995-04-18       Impact factor: 11.598

9.  Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.

Authors:  Darja Kanduc; Candida Fasano; Giovanni Capone; Antonella Pesce Delfino; Michele Calabrò; Lorenzo Polimeno
Journal:  J Immunol Res       Date:  2015-10-19       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.